RT Journal Article
T1 Venoarterial extracorporeal membrane oxygenation with or without simultaneous intra-aortic balloon pump support as a direct bridge to heart transplantation: results from a nationwide Spanish registry.
A1 Barge-Caballero, Gonzalo
A1 Castel-Lavilla, María A
A1 Almenar-Bonet, Luis
A1 Garrido-Bravo, Iris P
A1 Delgado, Juan F
A1 Rangel-Sousa, Diego
A1 González-Costello, José
A1 Segovia-Cubero, Javier
A1 Farrero-Torres, Marta
A1 Lambert-Rodríguez, José Luis
A1 Crespo-Leiro, María G
A1 Hervás-Sotomayor, Daniela
A1 Portolés-Ocampo, Ana
A1 Martínez-Sellés, Manuel
A1 De la Fuente-Galán, Luis
A1 Rábago-Juan-Aracil, Gregorio
A1 González-Vílchez, Francisco
A1 Mirabet-Pérez, Sonia
A1 Muñiz, Javier
A1 Barge-Caballero, Eduardo
K1 Extracorporeal membrane oxygenation
K1 Heart transplantation
K1 Intra-aortic balloon pump
AB To investigate the potential clinical benefit of an intra-aortic balloon pump (IABP) in patients supported with venoarterial extracorporeal membrane oxygenation (VA-ECMO) as a bridge to heart transplantation (HT). We studied 169 patients who were listed for urgent HT under VA-ECMO support at 16 Spanish institutions from 2010 to 2015. The clinical outcomes of patients under simultaneous IABP support (n = 73) were compared to a control group of patients without IABP support (n = 96). There were no statistically significant differences between the IABP and control groups with regard to the cumulative rates of transplantation (71.2% vs 81.2%, P = 0.17), death during VA-ECMO support (20.6% vs 14.6%, P = 0.31), transition to a different mechanical circulatory support device (5.5% vs 5.2%, P = 0.94) or weaning from VA-ECMO support due to recovery (2.7% vs 0%, P = 0.10). There was a higher incidence of bleeding events in the IABP group (45.2% vs 25%, P = 0.006; adjusted odds ratio 2.18, 95% confidence interval 1.02-4.67). In-hospital postoperative mortality after HT was 34.6% in the IABP group and 32.5% in the control group (P = 0.80). One-year survival after listing for urgent HT was 53.3% in the IABP group and 52.2% in the control group (log rank P = 0.75). Multivariate adjustment for potential confounders did not change this result (adjusted hazard ratio 0.94, 95% confidence interval 0.56-1.58). In our study, simultaneous IABP therapy in transplant candidates under VA-ECMO support did not significantly reduce morbidity or mortality.
YR 2019
FD 2019
LK http://hdl.handle.net/10668/14200
UL http://hdl.handle.net/10668/14200
LA en
DS RISalud
RD Apr 11, 2025